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ORIGINAL ARTICLE
Adolescent and young adult (AYA) lymphoma survivors report lower health-
related quality of life compared to a normative population: results from the
PROFILES registry
Olga Hussona, Judith B. Prinsa, Suzanne E. J. Kaalb, Simone Oerlemansc, Wendy B. Stevensd, Bradley Zebracke,
Winette T. A. van der Graafb,f and Lonneke V. van de Poll-Fransec,g,h
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Radboud University Medical Center, Nijmegen, The Netherlands; cNetherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The
Netherlands; dDepartment of Haematology, Radboud University Medical Center, Nijmegen, The Netherlands; eUniversity of Michigan School
of Social Work, Ann Arbor, MI, USA; fInstitute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK; gCoRPS-Centre of
Research on Psychology in Somatic diseases, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands;
hDivision of Psychosocial Oncology and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands
ABSTRACT
Background: Trying to simultaneously achieve developmental milestones and cope with a life-threat-
ening disease may place adolescents and young adults (AYAs) at risk for impaired health-related qual-
ity of life (HRQoL) later in life. The aim of this study was to examine differences in HRQoL between
AYA lymphoma survivors and a normative population and to determine sociodemographic, clinical and
long-term symptom-related factors associated with HRQoL.
Material and methods: This study was part of a longitudinal, population-based survey among lymph-
oma survivors diagnosed between 1999 and 2012. The AYA survivor sample (18–39 years at time diag-
nosis) was compared to a sex- and age-matched normative population on HRQoL (EORTC-QLQ-C30)
and psychological distress (HADS). Multiple linear regression analyses were conducted to determine
factors associated with HRQoL among survivors.
Results: One hundred and ninety-eight AYA lymphoma survivors (58%) responded to the study invita-
tion. Compared to an age- and sex-matched normative population (N¼ 380), significantly and clinically
relevant poorer HRQoL was observed for AYA lymphoma survivors in seven specific domains of HRQoL:
physical, role, cognitive, emotional, social functioning, fatigue and financial difficulties (all p< 0.05). In
addition, AYA lymphoma survivors less often had a spouse/partner and more often had a lower educa-
tional level compared to the normative population. Linear regression analyses showed that being
unemployed, female gender, having one or more comorbid conditions, high levels of fatigue and psy-
chological distress were most strongly associated with HRQoL.
Conclusions: These findings identify specific domains of life in which cancer has a significant and
long-term impact for AYA lymphoma survivors. Future investigations are needed to identify and test
administrations and timing of psychosocial support interventions having potential to reduce long-term
late effects in specific HRQoL domains and promote function and adaptability after cancer treatment.
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In The Netherlands, each year approximately 4000 people are
diagnosed with non-Hodgkin lymphoma (NHL) and 450 with
Hodgkin lymphoma (HL) [1]. Nearly 4% of the NHL and 38%
of the HL patients are diagnosed within the adolescent and
young adult (AYA) age range of 18–39 years. Lymphoma is
one of the most common cancers diagnosed at AYA age,
affecting both males and females [2]. Advances in early can-
cer detection, diagnosis, and treatments have noticeably
improved survival rates of patients with lymphoma [3].
Epidemiological data from the US, however, suggest that
five-year survival rates have not improved to the same
extent in AYAs as in children or older adults for several can-
cers including lymphoma [4]. Three potential explanations
are a patient and doctors delay in diagnosis; cancers
diagnosed at AYA age may be biologically distinct from
those diagnosed at older or younger ages; and clinical trial
participation is extremely low in this age group [5]. Although
the improvement in survival of AYAs with cancer lags behind,
the five-year overall survival is still 95% for HL and 76% for
NHL [4].
Adolescence and young adulthood is a challenging period
of physical, emotional, cognitive and social development [6].
Important and complex age-related developmental tasks need
to be achieved, such as forming one’s own identity and a
healthy body image, establishing autonomy, responsibility
and independence, finishing education and starting a career,
getting a relationship and having children [6]. A cancer
diagnosis may have profound effects on the lives of AYAs,
CONTACT Olga Husson Olga.Husson@radboudumc.nl Radboud University Medical Centre, Department of Medical Psychology, PO Box 9101, 6500 HB
Nijmegen, The Netherlands
 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
ACTA ONCOLOGICA, 2017
VOL. 56, NO. 2, 288–294
http://dx.doi.org/10.1080/0284186X.2016.1267404
D
ow
nl
oa
de
d 
by
 [R
ad
bo
ud
 U
niv
ers
ite
it N
ijm
eg
en
] a
t 0
4:1
2 0
2 O
cto
be
r 2
01
7 
interfering with the attainment of these normal develop-
mental milestones. Cancer-related issues such as premature
confrontation with mortality, changes in physical appear-
ance, increased dependence on parents, disruptions of
social life and school/employment because of treatment,
and potential loss of reproductive capacity may become
particularly distressing and could negatively impact their
health-related quality of life (HRQoL) [6]. Understanding
HRQoL outcomes among AYA lymphoma survivors is
important to identify who is at risk for poor outcomes and
to determine potential relevant services and resources
required to serve them. This population-based study aims
to: (1) assess HRQoL in AYA lymphoma survivors and com-
pare it to an age- and sex-matched normative population
and (2) identify sociodemographic, clinical and long-term
symptom-related factors associated with HRQoL for this
aged-defined population.
Methods
Setting and population
This study is part of a dynamic, longitudinal, population-
based survey of lymphoma patients registered in The
Netherlands Cancer Registry (NCR). The NCR records data on
all patients who are newly diagnosed with cancer in The
Netherlands. The NCR was used to select all survivors who
were diagnosed with indolent (including chronic lymphocytic
leukemia) and aggressive B-cell NHL or HL, as defined by the
International Classification of Diseases for Oncology-3 codes
(ICD-O-3), between 1 January 1999 and 1 June 2012. Patients
from 18 hospital locations and two large radiotherapy insti-
tutes in the southern part of The Netherlands, an area with
2.3 million inhabitants, were selected. Survivors who had
cognitive impairment or were too ill at time of the study
[according to advice from (former) treating specialist] or died
prior to the start of the study (according to the NCR, hospital
records, and the Central Bureau for Genealogy) were
excluded. Ethical approval for the study was obtained from
the local certified Medical Ethics Committee of the Maxima
Medical Center Veldhoven.
For this study we only used data of patients aged 18–39
years at time of diagnosis as this is the AYA age range in
The Netherlands.
Data collection
Data collection was done within Patient Reported Outcomes
Following Initial treatment and Long-term Evaluation of
Survivorship (PROFILES). PROFILES is a registry for the study
of the physical and psychosocial impact of cancer and its
treatment from a dynamic, growing population-based cohort
of both short- and long-term cancer survivors. PROFILES con-
tains a large web-based component and is linked directly to
clinical data from the NCR. Details of the data collection
method were previously described [7].
In May 2009, patients diagnosed between January 1999
and January 2009 were included in the study and received
the first questionnaire. In November 2009, May 2011, May
2012 and May 2013, patients newly diagnosed up to 1 June
2012 were subsequently invited to participate.
Study measures
Health-related quality of life – EORTC-QLQ-C30
HRQoL was measured by the European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC-QLQ-C30) [8]. This 30-item HRQoL ques-
tionnaire consists of five functional scales (physical, role, cogni-
tive, emotional and social), a global quality of life scale (overall
health and overall quality of life during the past week), three
symptom scales and a number of single items assessing com-
mon symptoms and perceived financial impact of the disease.
After linear transformation, all scales and single item measures
range in score from 0 to 100. A higher score on the functional
scales and global QoL means better functioning and HRQoL,
whereas a higher score on the symptom scales means more
complaints. Clinical important differences were determined
according to the guidelines of the EORTC Quality of Life Group
[9]. This size effect as measured by the EORTC-QLQ-C30 is div-
ided into four size classes: large (one representing unequivocal
clinical relevance), medium (likely to be clinically relevant, but
to a lesser extent), small (subtle but, nevertheless, clinically
relevant) and trivial (circumstances unlikely to have any clinical
relevance or where there was no difference).
Psychological distress (anxiety and depression) – HADS
Psychological distress was assessed with the Hospital Anxiety
and Depression Scale (HADS), with seven items each for
assessing symptoms of anxiety and depression [10]. All items
were scored on a zero- to three-point scale, with higher
scores indicating more symptoms. Clinically relevant differen-
ces were determined according to Norman’s rule of thumb
¼0.5 standard deviation [11].
Sociodemographic and clinical characteristics
Clinical information was available from the NCR that
routinely collects data on tumor characteristics, including
date of diagnosis, tumor grade, histology, Ann Arbor stage,
primary treatment and patients’ background characteristics,
including sex and date of birth. Comorbidity at the time of
survey was categorized according to the Self-administered
Comorbidity Questionnaire, assessing the prevalence of 14
comorbidities including heart disease, stroke, high blood
pressure, COPD/asthma, diabetes, stomach disease, kidney
disease, liver disease, anemia, depression, thyroid disease,
osteoarthritis, back pain, and rheumatoid arthritis. Self-
designed questions on educational level (high/intermediate/
low), partnership (yes/no) and occupation (yes/no) were
added to the questionnaire.
Normative population
Normative population data was obtained from CentERpanel,
an online household panel that is representative for the
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Dutch population. The process of the annual data collection,
which started in 2009 by our study group, has been
described elsewhere [12]. The data wave in 2011 included
assessment of HRQoL. From the 2040 (82%) respondents 18
years, a normative sample (n¼ 380) was matched on age at
time of questionnaire completion and sex.
Statistical analyses
Differences in sociodemographic and clinical characteristics
between respondents and non-respondents or survivors with
unverifiable addresses, and between AYA lymphoma survi-
vors and an age- and sex-matched normative population,
were examined with t-tests or analysis of variance (ANOVA)
for continuous variables and v2-tests for categorical variables,
where appropriate.
The same analytical techniques were used to determine dif-
ferences in HRQoL and distress between the AYA lymphoma
survivors and an age- and sex-matched normative population.
Hierarchical linear regression models were conducted to
identify associations of demographic and clinical characteristics,
long-term symptoms and psychological distress with HRQoL
among AYA lymphoma survivors. The models were composed
as follows: (1) demographicsþ clinical variables; (2) demo-
graphicsþ clinical variablesþ long-term symptoms (fatigue,
pain, insomnia, financial difficulties); (3) demographicsþ clinical
variablesþpsychological distress (anxiety, depression). All stat-
istical tests were two-sided and considered significant if
p< 0.05. All analyses were conducted using SPSS version 22.0
(Statistical Package for Social Sciences, Chicago, IL).
Results
Patient and tumor characteristics
Of the 360 survivors selected from the NCR, 18 were excluded
because of death or too ill at time of study. The questionnaire
was completed by 198 survivors (58%). No differences were
found between respondents, non-respondents (n¼ 63; 18%)
and survivors with unverifiable addresses (n¼ 81; 24%) with
regard to age, sex, time since diagnosis, primary treatment,
lymphoma type and disease stage (data not shown).
AYA lymphoma survivors differed from the age- and sex-
matched normative population in that AYA lymphoma survi-
vors less often had a partner (p< 0.01) and more often had a
lower educational level (p< 0.01) at time of questionnaire
completion (n¼ 380) (Table 1).
Differences in HRQoL and psychological distress
between AYA lymphoma survivors and normative
population
AYA lymphoma survivors scored significantly worse on role,
cognitive, social (all small to medium clinical importance),
physical and emotional functioning (both trivial clinical
importance) compared to the age- and sex-matched norma-
tive population (Figure 1). No significant differences were
found for global quality of life.
AYA lymphoma survivors had significantly more symptoms
of fatigue and reported more financial difficulties (respect-
ively of small and medium clinical importance) compared to
the normative population (Figure 1).
No statistically significant difference between survivors and
the normative population was found for psychological distress.
Factors associated with HRQoL of AYA lymphoma
survivors
Model 1 of the hierarchical regression analyses showed that
age at cancer diagnosis was negatively associated with
Table 1. Sociodemographic and clinical characteristics of AYA lymphoma
patients compared to normative population.
AYA cancer
patients
N¼ 198
N (%)
Normative
population
N¼ 380
N (%) p-Value
Sex (male) 112 (57%) 204 (54%) 0.47
Age at time diagnosis – M (SD) 30.4 (6.4) NA
Age at time diagnosis NA
18–25 years 55 (28%)
26–39 years 143 (72%)
Age at time surveya – M (SD) 34.7 (7.4) 35.2 (8.0) 0.50
Age at time surveya 0.20
18–29 years 45 (23) 83 (22)
30–35 years 59 (30) 85 (22)
36–40 years 45 (23) 104 (27)
41 years 49 (25) 108 (28)
Years since diagnosis – M (SD) 4.2 (2.7) NA
Years since diagnosis NA
<2 years 54 (27%)
2–5 years 69 (35%)
>5 years 75 (38%)
Tumor type NA
Hodgkin lymphoma 89 (45%)
Non-Hodgkin lymphoma 109 (55%)
Stageb NA
I 43 (22%)
II 84 (42%)
III 31 (16%)
IV 34 (17%)
Unknown 6 (3%)
Primary treatment NA
Wait and see 15 (8%)
Chemotherapy alone 85 (43%)
Radiotherapy alone 9 (4%)
Stem cell transplantation 1 (1%)
Radiotherapy and chemotherapy 82 (41%)
Other therapies 5 (3%)
Missing 1 (1%)
Number of comorbid
conditionsd – M (SD)
1.3 (3.0) 0.6 (1.3) <0.01
Number of comorbid conditions 0.01
None 122 (62%) 246 (65%)
One 36 (18%) 90 (24%)
Two or more 40 (20%) 44 (12%)
Partner (yes) 137 (69%) 312 (82%) <0.01
Job (yes) 132 (75%) 301 (79%) 0.22
Educational level <0.01
Low 53 (27%) 10 (3%)
Middle 112 (58%) 219 (58%)
High 29 (15%) 149 (39%)
aMatching was based on age at questionnaire completion and sex; bDisease
stage was not available for some indolent non-Hodgkin lymphoma patients;
22 patients had indolent non-Hodgkin lymphoma and 87 had aggressive
non-Hodgkin lymphoma; dComorbid conditions that were assessed included
heart disease, stroke, high blood pressure, lung disease (e.g., COPD, asthma),
diabetes, ulcer, kidney disease, liver disease, anemia, thyroid disease, depres-
sion, rheumatism, back pain, osteoarthritis.
M: mean; NA: not applicable; SD: standard deviation.
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cognitive and social functioning (Table 2). Female sex was
negatively associated with physical, role, cognitive and social
functioning. Being unemployed and having one or more
comorbid conditions were negatively associated with all
scales, except social functioning for comorbid conditions.
Explained variances ranged from 0.19 to 0.33.
In Model 2 we added fatigue which was independently,
negatively associated with all functioning scales and global
quality of life. Pain was negatively associated with physical
functioning and global quality of life. Insomnia was negatively
associated with emotional functioning and positively associ-
ated with social functioning, whereas financial difficulties were
negatively associated with physical and social functioning.
Explained variances ranged from 0.48 to 0.63.
Adding anxiety in Model 3 showed that anxiety was inde-
pendently, negatively associated with physical, emotional
and cognitive functioning, whereas depression was nega-
tively associated with all functioning scales and global quality
of life. Explained variances ranged from 0.34 to 0.64.
Discussion
In this study, AYA lymphoma survivors reported a consider-
ably lower HRQoL compared to an age- and sex-matched
normative population, with the largest differences for cogni-
tive, role and social functioning, fatigue and financial difficul-
ties. Our results are in line with those of two previously
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Figure 1. Comparison of HRQoL (a), long-term symptoms (b) and psychological distress scores (c) between patients and normative population. Note: p< 0.05 and
trivially clinically important difference; p< 0.05 and small clinically important difference; p< 0.05 and medium clinically important difference. (a) Scores can
range from 0 to 100 with higher scores implying a better HRQoL. (b) Scores can range from 0 to 100 with higher scores implying more symptoms. (c) Scores can
range from 0 to 21 with higher scores implying more psychological distress.
ACTA ONCOLOGICA 291
D
ow
nl
oa
de
d 
by
 [R
ad
bo
ud
 U
niv
ers
ite
it N
ijm
eg
en
] a
t 0
4:1
2 0
2 O
cto
be
r 2
01
7 
conducted studies among heterogeneous groups of AYA sur-
vivors in terms of tumor types [13,14]. Data from the
Adolescent and Young Adult Health Outcomes and Patient
Experience (AYA HOPE) study, a population-based cohort of
523 AYA cancer patients 6–14 months post-diagnosis at
study entry showed that AYA cancer survivors reported sig-
nificantly worse HRQoL across both physical and mental
scales of the Short Form-12 (SF-12) compared to population
norms [14]. This study found the greatest deficits for AYA
cancer survivors in limitations to physical and emotional
roles, physical and social functioning and general health. A
German study among 117 AYA cancer survivors within the
first five years after diagnosis, using the EORTC-QLQ-C30 to
assess HRQoL, found that AYA cancer survivors reported
poorer outcomes on all scales (physical, role, emotional, cog-
nitive and social functioning) compared to a normative popu-
lation [13]. The highest point differences were found for
social, role and emotional functioning.
Poorer functioning among AYA lymphoma survivors may
mirror the cumulative effects of normal developmental chal-
lenges in AYAs (e.g., education, work, relationships, starting
families) while dealing with the aftermath of cancer and its
treatment. Our finding that AYA lymphoma survivors less
often had a partner, more often a lower educational level
and more financial problems compared to an age- and sex-
matched normative population, may indicate that relation-
ships, school/work and finances are negatively impacted and
sustained over time by a diagnosis of and treatment for
lymphoma.
Although we did not find a significant difference in
employment status between AYA lymphoma survivors and
the normative population, not having a job was strongly
associated with all HRQoL functioning scales. It could be
that reasons for unemployment are more often disease or
disability related among AYA cancer survivors compared to
controls [15]. Not having a job could reflect a higher
severity and impact of the disease. A recent study showed
that AYA cancer survivors who reported their cancer treat-
ment was ‘very intensive’ and those who had quit work/
school after being diagnosed were more likely to report
that cancer negatively affected their work/school after diag-
nosis, with more than half reporting problems with mem-
ory and attention [16], indicating problems with cognitive
functioning. Those who remain employed during treatment
Table 2. Standardized betas of hierarchical multiple linear regression analyses evaluating the association of demographic and clinical characteristics, symptoms
and psychological distress with HRQoL among AYA lymphoma patients.
Global quality
of life Beta
Physical
functioning Beta
Role
functioning Beta
Emotional
functioning Beta
Cognitive
functioning Beta
Social
functioning Beta
Model 1: Demographics and clinical variables
Age time diagnosis
26 years (ref
18–25 years)
0.09 0.12 0.06 0.10 0.21 0.16
Sex
Females (ref males) 0.04 0.24 0.16 0.04 0.21 0.22
Education
High vs. medium 0.06 0.01 0.12 0.09 0.06 0.08
High vs. Low 0.05 0.03 0.05 0.05 0.02 0.03
Partner
Partner (ref no
partner)
0.04 0.01 0.04 0.13 0.03 0.11
Job
No (ref yes) 0.34 0.35 0.25 0.21 0.23 0.16
Time since
diagnosis
0.06 0.03 0.12 0.02 0.12 0.05
Tumor type
HL (ref NHL) 0.01 0.05 0.07 0.07 0.02 0.07
Stage
1 vs. 2 0.15 0.08 0.05 0.16 0.08 0.15
1 vs. 3 0.13 0.08 0.01 0.10 0.04 0.09
1 vs. 4 0.14 0.03 0.03 0.04 0.11 0.14
1 vs. missing 0.04 0.03 0.09 0.06 0.04 0.02
Comorbid conditions
0 vs. 1 0.10 0.17 0.12 0.14 0.18 0.14
1 vs. 2 or more 0.19 0.20 0.21 0.34 0.17 0.12
R2 0.23 0.33 0.24 0.26 0.25 0.19
Model 2: Model 1 þ long-term symptoms
Fatigue 0.40 0.41 0.66 0.41 0.50 0.43
Pain 0.25 0.25 0.13 0.05 0.01 0.01
Insomnia 0.07 0.05 0.01 0.28 0.08 0.17
Financial problems 0.15 0.17 0.06 0.08 0.05 0.47
R2 0.56 0.63 0.63 0.55 0.48 0.55
Model 3: Model 1 þ psychological distress
Anxiety 0.15 0.23 0.15 0.51 0.31 0.12
Depression 0.52 0.18 0.30 0.27 0.29 0.40
R2 0.50 0.45 0.36 0.64 0.47 0.34
p< 0.05; p< 0.01.
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or reenter shortly after treatment have probably less trou-
bles to maintain normalcy and social reintegration with
friends, peers, and others, which minimizes life disruption
and optimizes social functioning [17]. Furthermore, a
lymphoma diagnosis could significantly impact work plans.
Not all AYA lymphoma survivors are able to get the type
of job or do the kind of work they would have liked to
do and need to adjust their goals as a result of their can-
cer, which by itself could negatively affect HRQoL. This is
illustrated by a study reporting that AYA cancer survivors
felt ‘left behind’ in their career or job trajectories com-
pared with their peers [18].
Problems with getting back to work or finding a job after
cancer may also be related to the higher financial difficulties
experienced by AYA lymphoma survivors. In addition, there
may be financial strains related to the cost of treatment and
loss of pay resulting from time off from work, but AYA cancer
survivors often also have lower earnings as they are in the
beginning stages of work and vocational development.
Financial independence is considered a hallmark of adult-
hood, AYA cancer survivors may need to rely on significant
others for financial support, which can result in feelings of
dependency and loss of control [18].
Interference with work or school and financial difficulties
can both result in psychological distress. Our finding that
fewer AYA lymphoma survivors had a partner compared to
the normative population could indicate high relationship
concerns. On the one hand, a negative body image, infertility
concerns, or feelings of ‘abnormality’ as a result of cancer
and its treatment may lead to troubles with starting a serious
relationship [19], on the other hand, emotional stress and
financial burdens of cancer can negatively impact AYA
lymphoma survivors’ relationship with their partner.
Relationship concerns by itself can lead to higher levels of
psychological distress [19]. In our study psychological distress
was strongly associated with HRQoL, however, distress levels
were not higher compared with population norms. Still, our
findings indicate the importance of age-appropriate psycho-
social support to reduce distress and help AYA lymphoma
survivors adjust to their illness.
Next to factors related to developmental milestones, age
and gender were also associated with HRQoL. Older AYA
lymphoma survivors had worse scores on cognitive and
social functioning, which may have to do with higher work-
related and social demands at time of diagnosis. Female gen-
der was associated with lower HRQoL. Women in general
have the tendency to report more problems and express
emotions more easily compared to men [13]. Therefore, the
association that we found should not lead to the conclusion
that male patients need less psychosocial support.
Another noteworthy observation was the lack of differen-
ces in HRQoL between short- and long-term AYA lymphoma
survivors. This is an interesting finding because it is an indi-
cation that deteriorated HRQoL scores do not improve over
time. No other clinical factors (type of lymphoma, disease
stage) were related to HRQoL. This is in congruence with the
current state of research suggesting that subjective appraisals
of cancer’s impact on one’s life may be more salient as con-
tributors to HRQoL than objective cancer-related clinical
factors (e.g., time since diagnosis, type or severity of treat-
ment) [20]. This research suggests that survivors who report
subjective appraisals, perceptions or experiences of how can-
cer has negatively affected their lives experience worse
HRQoL [20]. Given that perceptions are malleable and change
over time, cognitive and behavioral interventions that
reframe perceptions may have the potential to enhance
survivors’ HRQoL. However, we found that long-term symp-
toms such as fatigue were strongly associated with several
functioning scales, suggesting that post-treatment symptom
management would be helpful to diminish debilitating symp-
toms and improve functioning [14].
Despite the lower functioning scores of AYA lymphoma
survivors, no difference in global quality of life between AYA
lymphoma survivors and the normative population was
found. One possible but not yet well investigated explan-
ation could be that some AYA cancer survivors experience
post-traumatic growth post-treatment [21]. It will be interest-
ing for future research to identify factors that may underpin
the emergence of these positive psychological outcomes to
help development of interventions for AYA lymphoma survi-
vors who continue to report symptoms psychological
distress.
Limitations
This study has several limitations that should be mentioned.
First, the cross-sectional design limits the determination of
changes over time in AYA lymphoma survivors’ HRQoL.
Longitudinal studies are needed to assess within-person
changes in HRQoL to identify risk groups for persistent lower
levels of HRQoL for whom interventions are most needed.
Second, detailed follow-up treatment and relapse data was
lacking because the NCR registers only the primary diagnosis
and treatment procedures. Third, although the CentERpanel
is designed to be representative for the Dutch population,
due to selective response on our questionnaire we have
included a somewhat higher educated population. Fourth,
we did not make use of an AYA cancer-specific HRQoL meas-
ure, because there is a relative lack of measures developed
or validated in this population [22]. Qualitative research high-
lights the need for tools measuring domains, such as cogni-
tion, sexual and reproductive health and social relationships
[23]. An AYA-specific HRQoL instrument in research and clin-
ical practice will be instrumental in the objective evaluation
of the new psychosocial and supportive care interventions
that minimize or prevent long-term deleterious effects of
cancer but also promote positive adaptation, resilience, and
the achievement of age-specific developmental tasks. Fifth,
because lymphoma is a very heterogeneous disease with
respect to subtypes and treatment, our study can only
answer the question how a lymphoma diagnosis at AYA age
influenced HRQoL. However, the homogeneous study sample
with respect to tumor type could also be mentioned as a
strength of this study. Compared to other studies among
more heterogeneous groups of AYA cancer survivors, we
were able to show sex differences in HRQoL not related to
tumor type.
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Future perspectives
Overall, our findings support research into (early) psycho-
social interventions for AYA lymphoma survivors as well as
the need to manage long-term symptoms, provide financial
support and facilitate AYA lymphoma survivors’ involve-
ment in work and/or school. Due to the still relatively
small number of AYA survivors implementing age-appropri-
ate interventions might be a challenge. Nevertheless, the
recent developments of AYA-specific programs with multi-
disciplinary care teams to approach this area of need will
provide new opportunities [24]. In addition, new media
can facilitate AYA lymphoma survivors’ participation in their
own care and may become new modes of delivering
cost-effective and easy to disseminate psychosocial
support [25].
Conclusion
AYA lymphoma survivor report lower HRQoL scores com-
pared with the normative population. Although overall global
quality of life scores are good, impairments are experienced
in the domains of role, cognitive and social functioning,
fatigue and financial problems. Employment status, gender,
comorbid conditions, fatigue and psychological distress were
most strongly associated with HRQoL. Future intervention
studies should explore ways to timely address poor
functioning.
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